Literature DB >> 22722776

Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Michael N Neely1, Michael G van Guilder, Walter M Yamada, Alan Schumitzky, Roger W Jelliffe.   

Abstract

INTRODUCTION: Nonparametric population modeling algorithms have a theoretical superiority over parametric methods to detect pharmacokinetic and pharmacodynamic subgroups and outliers within a study population.
METHODS: The authors created "Pmetrics," a new Windows and Unix R software package that updates the older MM-USCPACK software for nonparametric and parametric population modeling and simulation of pharmacokinetic and pharmacodynamic systems. The parametric iterative 2-stage Bayesian and the nonparametric adaptive grid (NPAG) approaches in Pmetrics were used to fit a simulated population with bimodal elimination (Kel) and unimodal volume of distribution (Vd), plus an extreme outlier, for a 1-compartment model of an intravenous drug.
RESULTS: The true means (SD) for Kel and Vd in the population sample were 0.19 (0.17) and 102 (22.3), respectively. Those found by NPAG were 0.19 (0.16) and 104 (22.6). The iterative 2-stage Bayesian estimated them to be 0.18 (0.16) and 104 (24.4). However, given the bimodality of Kel, no subject had a value near the mean for the population. Only NPAG was able to accurately detect the bimodal distribution for Kel and to find the outlier in both the population model and in the Bayesian posterior parameter estimates.
CONCLUSIONS: Built on over 3 decades of work, Pmetrics adopts a robust, reliable, and mature nonparametric approach to population modeling, which was better than the parametric method at discovering true pharmacokinetic subgroups and an outlier.

Entities:  

Mesh:

Year:  2012        PMID: 22722776      PMCID: PMC3394880          DOI: 10.1097/FTD.0b013e31825c4ba6

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.

Authors:  R Jelliffe; D Bayard; M Milman; M Van Guilder; A Schumitzky
Journal:  Ther Drug Monit       Date:  2000-06       Impact factor: 3.681

2.  Prediction discrepancies for the evaluation of nonlinear mixed-effects models.

Authors:  France Mentré; Sylvie Escolano
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-13       Impact factor: 2.745

3.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings.

Authors:  Jeffrey S Barrett; Michael J Fossler; K David Cadieu; Marc R Gastonguay
Journal:  J Clin Pharmacol       Date:  2008-05       Impact factor: 3.126

Review 5.  Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician.

Authors:  Michael Neely; Roger Jelliffe
Journal:  J Clin Pharmacol       Date:  2010-02-12       Impact factor: 3.126

6.  Standardized visual predictive check versus visual predictive check for model evaluation.

Authors:  Diane D Wang; Shuzhong Zhang
Journal:  J Clin Pharmacol       Date:  2011-01-21       Impact factor: 3.126

7.  Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.

Authors:  Sylvain Goutelle; Laurent Bourguignon; Pascal H Maire; Michael Van Guilder; John E Conte; Roger W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

8.  Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.

Authors:  Michael Neely; Roger Jelliffe
Journal:  J Clin Pharmacol       Date:  2008-07-17       Impact factor: 3.126

  8 in total
  200 in total

1.  Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

Authors:  Arnold Louie; Weiguo Liu; Michael VanGuilder; Michael N Neely; Alan Schumitzky; Roger Jelliffe; Steven Fikes; Stephanie Kurhanewicz; Nichole Robbins; David Brown; Dodge Baluya; George L Drusano
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

2.  Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Authors:  Nathaniel J Rhodes; Walter C Prozialeck; Thomas P Lodise; Natarajan Venkatesan; J Nicholas O'Donnell; Gwendolyn Pais; Cameron Cluff; Peter C Lamar; Michael N Neely; Anil Gulati; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 3.  Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.

Authors:  Sofie Dhaese; Aaron Heffernan; David Liu; Mohd Hafiz Abdul-Aziz; Veronique Stove; Vincent H Tam; Jeffrey Lipman; Jason A Roberts; Jan J De Waele
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

4.  Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.

Authors:  Pier Giorgio Cojutti; Manuela Lugano; Elda Righi; Giorgio Della Rocca; Matteo Bassetti; William Hope; Federico Pea
Journal:  Eur J Clin Pharmacol       Date:  2018-07-21       Impact factor: 2.953

5.  A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.

Authors:  Ida Robertsen; Jean Debord; Anders Åsberg; Pierre Marquet; Jean-Baptiste Woillard
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

6.  Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study.

Authors:  Ahmed A Mahmoud; Sean N Avedissian; Abbas Al-Qamari; Tiffany Bohling; Michelle Pham; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2020-12       Impact factor: 6.447

7.  Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children.

Authors:  Jodi M Lestner; Andreas H Groll; Ghaith Aljayyoussi; Nita L Seibel; Aziza Shad; Corina Gonzalez; Lauren V Wood; Paul F Jarosinski; Thomas J Walsh; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.

Authors:  Cinzia Auriti; Marco Falcone; Maria Paola Ronchetti; Bianca Maria Goffredo; Sara Cairoli; Rosamaria Crisafulli; Fiammetta Piersigilli; Tiziana Corsetti; Andrea Dotta; Manjunath P Pai
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

9.  Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.

Authors:  Thomas Tängdén; Pier Giorgio Cojutti; Jason A Roberts; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

10.  Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction.

Authors:  Matteo Rinaldi; Pier Giorgio Cojutti; Eleonora Zamparini; Sara Tedeschi; Nicolò Rossi; Matteo Conti; Maddalena Giannella; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.